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Konstantinos K. Tsilidis, Mattias Johansson, Elio Riboli, Timothy J. Key, and Ruth C. Travis
A B S T R A C T
Purpose
Vasectomy is a commonly used form of male sterilization, and some studies have suggested that it
may be associated with an increased risk of prostate cancer, including more aggressive forms of the
disease. We investigated the prospective association of vasectomy with prostate cancer in a large
European cohort, with a focus on high-grade and advanced-stage tumors, and death due to prostate
cancer.
Patients and Methods
A total of 84,753 men from the European Prospective Investigation into Cancer and Nutrition (EPIC),
aged 35 to 79 years, provided information on vasectomy status (15% with vasectomy) at re-
cruitment and were followed for incidence of prostate cancer and death. We estimated the as-
sociation of vasectomy with prostate cancer risk overall, by tumor subtype, and for death due to
prostate cancer, using multivariable-adjusted Cox proportional hazards models.
Results
During an average follow-up of 15.4 years, 4,377 men were diagnosed with prostate cancer, in-
cluding 641 who had undergone a vasectomy. Vasectomy was not associated with prostate cancer
risk (hazard ratio [HR], 1.05; 95% CI, 0.96 to 1.15), and no evidence for heterogeneity in the as-
sociation was observed by stage of disease or years since vasectomy. There was some evidence of
heterogeneity by tumor grade (P = .02), with an increased risk for low-intermediate grade (HR, 1.14;
95%CI, 1.01 to 1.29) but not high-grade prostate cancer (HR, 0.83; 95%CI, 0.64 to 1.07). Vasectomy
was not associated with death due to prostate cancer (HR, 0.88; 95% CI, 0.68 to 1.12).
Conclusion
These ﬁndings from a large European prospective study show no elevated risk for overall, high-grade
or advanced-stage prostate cancer, or death due to prostate cancer in men who have undergone
a vasectomy compared with men who have not.
J Clin Oncol 35:1297-1303. © 2017 by American Society of Clinical Oncology. Licensed under the
Creative Commons Attribution 4.0 License: http://creativecommons.org/licenses/by/4.0/
INTRODUCTION
Vasectomy is a commonly used form of male
sterilization that has been performed globally in an
estimated 40 million to 60 million men.1 Although
a meta-analysis of ﬁve prospective cohort studies2
and a subsequent analysis in the Cancer Prevention
Study II (CPS-II)3 found no signiﬁcant elevated
risk of prostate cancer associated with vasectomy,
a recent investigation in the Health Professionals
Follow-Up Study (HPFS) has reported a signiﬁcant
increase in risk of high-grade (hazard ratio [HR],
1.22; 95% CI, 1.03 to 1.45) and advanced-stage
prostate cancer (HR, 1.20; 95% CI, 1.03 to 1.40)
associated with having a vasectomy.4
Various biologic mechanisms have been
suggested to explain an association of vasec-
tomy with prostate cancer, including immu-
nologic effects,5 cellular proliferation,6 and sex
hormone imbalances.7 However, none has been
clearly supported in humans. Differences in
health-seeking behaviors have been suggested as
a possible explanation for any association1,2,8,9;
men who have had a vasectomy may be more
likely to monitor their health, have a prostate-
speciﬁc antigen (PSA) test, and be diagnosed
with prostate cancer.4,10
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The current study investigated the association between va-
sectomy and prostate cancer risk in the European Prospective
Investigation into Cancer and Nutrition (EPIC), with a focus on
tumor stage and grade, and death due to prostate cancer. We also
examined the cross-sectional associations of vasectomy with PSA
testing and with circulating concentrations of seminal proteins.
PATIENTS AND METHODS
Study Population
EPIC included 142,239 men recruited at 19 centers in eight European
countries (Denmark, Germany, Greece, Italy, The Netherlands, Spain,
Sweden, and the United Kingdom).11 Recruitment was between 1992 and
2000, and at enrolment participants were mostly aged between 35 and
79 years. All participants provided written informed consent. Source pop-
ulations were generally identiﬁed by geographic administrative boundaries
constituting a sample of convenience invited in person or by mail to complete
baseline EPIC questionnaires. Center-speciﬁc recruitment criteria are out-
lined by Riboli et al.11 There was modest heterogeneity of study practices by
recruitment centers; estimates of response rates were between approximately
22% and 60% across centers.12-15 Approval for the study was obtained from
the ethical review boards of the participating institutions and the In-
ternational Agency for Research on Cancer.
Information about lifestyle factors (ie, smoking status, physical
activity, and alcohol consumption), sociodemographic characteristics
(ie, marital status and educational attainment), diet, and medical his-
tory (including vasectomy status and age at vasectomy) was collected via
questionnaires at recruitment. For 6,771 (97.3%) of 6,961 men in the
EPIC-Oxford cohort who completed a follow-up questionnaire, history of
PSA testing and age at PSA test were collected 10 years after recruitment.
Weight and height were measured at recruitment, except for part of the
Oxford cohort for whom height and weight were self-reported. Body mass
index (BMI) was calculated as weight in kilograms divided by height in
meters squared.
This analysis includes 84,753 men from Denmark, Germany, Spain,
and the United Kingdomwho provided information on vasectomy status at
recruitment; data on vasectomy were missing for 712 men for these
countries. Information on vasectomy was not available for men in Italy,
The Netherlands, or Sweden (n = 45,960). Additionally, in the Greek
recruitment center, only four men had had a vasectomy and there were no
exposed incident cases of prostate cancer; therefore, because all analyses
were stratiﬁed by recruitment center, Greek participants were excluded
(n = 10,814).
Ascertainment of Prostate Cancer
Information on cancer diagnosis was obtained from national and
regional registries for Denmark, Spain, and the United Kingdom. For
Germany, active follow-up, including inquiries by mail or telephone to
participants, municipal registries, regional health departments, physicians,
and hospitals, was used. Information on death, including death due to
prostate cancer as the underlying cause, was obtained from death cer-
tiﬁcates; available evidence suggests information on death due to prostate
cancer is accurate.16-19 For analyses of incidence, follow-up continued
from date of recruitment to date of any primary cancer diagnosis, death, or
last completed follow-up (Denmark, December 31, 2012; Germany,
January 5, 2011; Spain, October 19, 2013; and the United Kingdom,
December 31, 2012), whichever was ﬁrst. For analyses of death due to
prostate cancer, follow-up continued until death or date of last completed
follow-up. During the follow-up period, 4,377 men developed prostate
cancer (International Classiﬁcation of Diseases 10th revision codes,
C6120).
Cancer-stage information was available for 2,733 (63.3%) of par-
ticipants. The number of participants with tumor-node-metastasis (TNM)
staging of T1-T3, N0/Nx, and M0/Mx, or stage coded in the recruitment
center as having localized disease was 2,100; the number of participants
identiﬁed as having advanced prostate cancer (T4 and/or N1-N3, and/or
M1, or stage coded in the recruitment center as metastatic) was 633. Grade
information was available for 2,986 (68.2%) of participants. The number
of participants with low-intermediate grade (Gleason score , 8, or grade
coded as well, moderately, or poorly differentiated) was 2,438. The number
of participants identiﬁed as high-grade prostate cancer (Gleason score$ 8,
or grade coded as undifferentiated) was 544. There was a small difference in
the frequency of vasectomy between patients with prostate cancer who did
and did not have tumor subtype information; thirteen percent of par-
ticipants with information on tumor stage had had a vasectomy, compared
with 17% of participants without tumor stage information; and 14% of
participants with information on tumor grade had had a vasectomy,
compared with 16% of participants without tumor grade information. By
the end of follow-up, 15,285 men had died, of whom 632 had died of
prostate cancer.
Laboratory Assays
Assay data were available for men in the EPIC cohort who had been
selected as controls in an unpublished, matched nested case-control study
of prostate cancer. Each control had been selected at random from the
cohort of men who were alive and free of cancer (excluding nonmelanoma
skin cancer) at the time of diagnosis of their index case, using an incidence
density sampling protocol (further details on matching methods can be
found in Travis et al).21 Immunoassay measurements for total PSA, free
PSA,22 intact PSA, human kallikrein 2 (hK2),23,24 and microseminoprotein-b
(MSP)25,26 were conducted in samples from 1,469 men on the AutoDELFIA
1235 automatic immunoassay system (PerkinElmer, Turku, Finland) at the
Wallenberg Research Laboratories, Department of Translational Medicine,
Lund University, Ska˚ne University Hospital, Sweden.27,28 All intra- and
interassay coefﬁcients of variation were , 9%.
Statistical Analyses
Cox proportional hazards models were used to estimate the HRs and
95% CIs for prostate cancer incidence, and were used separately for death
due to prostate cancer, using age as the underlying time variable. The slope
of the Schoenfeld residuals over time was used to verify the proportionality
of hazards.
All models were stratiﬁed by the particpant’s age at enrolment (, 50,
50-54, 55-59, 60-64, 65-69, and$ 70 years) and EPIC recruitment center.
Multivariable models were adjusted for factors suspected to be associated
with prostate cancer or vasectomy, including education (less than uni-
versity, university graduate), smoking status (never, former, current), BMI
(, 20, 20-24, 25-29, and $ 30 kg/m2), alcohol intake (, 8, 8-15, 16-39,
and$ 40 g/d ethanol), and physical activity (inactive, moderately inactive,
moderately active, active).29 Missing values were assigned to separate
categories for education (3.8%), smoking status (1.5%), BMI (0.6%), and
physical activity (0.8%), and missing indicators were used in the statistical
models. Additional analyses were conducted adjusting for marital status
(single, married, divorced, or widower); however, this information was
only available for Germany and the United Kingdom. Adjustment was also
made for protein from dairy sources (fourths) because this was previously
found to be associated with prostate cancer in the EPIC cohort.30
Subgroup analyses were conducted according to patient’s age at
vasectomy (, 38 v$ 38 years), time since vasectomy (, 25 v$ 25 years),
by median BMI and alcohol consumption, physical activity, marital status,
educational attainment, and smoking status. Additional analyses were
conducted by tumor subtypes: stage (localized v advanced) and tumor
grade (low-intermediate v high). Tests for heterogeneity in the association
between vasectomy and prostate cancer were likelihood ratio tests for
subgroup analyses and competing risk methods31 for stage and grade
analyses. Country-speciﬁc associations were estimated using the Cox re-
gression models and tests for heterogeneity were by likelihood ratio tests.
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For a subset of 6,771 men in the EPIC-Oxford subcohort, for whom
data on PSA testing were available, we investigated the suggestion that any
association between vasectomy and prostate cancer is inﬂuenced by dif-
ferences in the use of PSA testing in men who have undergone vasectomy.2
We used multivariable logistic regression to estimate the association of
vasectomy with having a PSA test, adjusted for BMI and age at completion
of questionnaire.
The cross-sectional association of vasectomy status with naturally
logarithm-transformed plasma analyte concentrations (MSP, PSA [total,
free, intact, free-to- total], and hK2) was evaluated using analysis of
variance to compare geometric means adjusted for age at recruitment,
BMI, recruitment center, and laboratory batch.
RESULTS
Overall, 84,743 men were followed up for a median of 15.4 years
(range, 0-20 years), of whom 4,377 developed prostate cancer. The
mean age at recruitment was 53 years, which ranged from 50 years
in Spain to 56 years in Denmark. The mean age at diagnosis of
prostate cancer was 68 years, with a range of 65 years in Germany to
71 years in the United Kingdom. The proportion of men with self-
reported vasectomy was 15% (n = 12,712), which ranged from
4.1% (n = 863) in Germany to 20.5% (n = 4,640) in the United
Kingdom. For the 97.9% (n = 12,455) of men who had undergone
vasectomy and who also provided age at vasectomy, median age at
vasectomy was 38 years.
Compared with men without a vasectomy, men with a vas-
ectomy were, on average, older at recruitment (54 years v 52 years),
had a higher education level (university graduate, 33% v 26%), and
were less physically active (14% v 19%). Men with a vasectomy
were more likely to be married (91% v 80%). Vasectomy status also
varied signiﬁcantly by smoking status and alcohol consumption,
although the magnitude of the differences was small (Table 1).
Additionally, an analysis in the EPIC-Oxford subcohort showed
that menwho had undergone a vasectomy were 54%more likely to
have had a PSA test when compared with menwithout a vasectomy
(odds ratio, 1.54; 95% CI, 1.35 to 1.76).
Vasectomy and Prostate Cancer
Of the 4,377 men with prostate cancer for whom vasectomy
status was available, 641 (14.6%) had a self-reported vasectomy at
recruitment. Vasectomy was not signiﬁcantly associated with
prostate cancer risk after stratiﬁcation by recruitment center and
age at recruitment (HR, 1.05; 95% CI, 0.96 to 1.15). Additional
adjustment for BMI, smoking status, marital status, educational
attainment, alcohol consumption, physical activity, and protein
from dairy sources did not alter results (HR, 1.05; 95% CI, 0.96 to
1.15). No evidence of heterogeneity was found in the association
between vasectomy and prostate cancer by the stage of disease
(P = .6) or recruitment country (P = .09; data not shown).
However, there was evidence of heterogeneity by tumor grade
(P = .02); vasectomy was associated with an increased risk of low-
intermediate grade (HR, 1.14; 95% CI, 1.01 to 1.29) but not of
high-grade prostate cancer (HR, 0.83; 95% CI, 0.64 to 1.07)
(Table 2). Additionally, there was no signiﬁcant association of
vasectomy with death due to prostate cancer (HR, 0.88; 95% CI,
0.68 to 1.12).
There was signiﬁcant heterogeneity in the association by
median age at vasectomy (38 years) (P = .04). Compared with men
who had not had a vasectomy, men who had a vasectomy when
they were younger than the median age were at a signiﬁcantly
increased risk of prostate cancer (HR, 1.18; 95% CI, 1.03 to 1.35),
whereas there was no signiﬁcant association with prostate cancer in
men who had a vasectomy when they were older than the median
age (HR, 0.99; 95% CI, 0.89 to 1.09). There was also signiﬁcant
heterogeneity for the association of vasectomy with prostate cancer
by median-deﬁned strata of alcohol consumption (P = .03; data not
shown). In men with below median alcohol consumption, those
who had a vasectomy were at a signiﬁcantly increased risk of
prostate cancer (HR, 1.16; 95% CI, 1.02 to 1.31) compared with
men without a vasectomy, whereas for men with above median
alcohol consumption, vasectomy was not associated with prostate
cancer (HR, 0.96; 95% CI, 0.84 to 1.08). No heterogeneity was
observed for subgroup analyses by BMI, physical activity, marital
status, educational attainment, or smoking status (data not
shown). There was no heterogeneity (P = .9) in the associationwith
prostate cancer risk by time since vasectomy.
Circulating Concentrations of Seminal Proteins and
Vasectomy
Compared with men without a vasectomy, men with a vasec-
tomy had signiﬁcantly higher concentrations of MSP (multivariable-
Table 1. Characteristics of Men in the EPIC Cohort by Vasectomy Status
at Recruitment (N = 84,753)
Characteristic
Without Vasectomy
(n = 72,041)
With Vasectomy
(n = 12,712)
Age, years 54.0 (48.0-60.0) 52.0 (47.0-57.0)
Weight, kg 80.5 (73.3-88.5) 80.1 (73.4-88.0)
Height, cm 175.0 (170.0-179.8) 175.0 (170.5-180.0)
BMI, kg/m2 26.4 (24.2-28.9) 26.2 (24.2-28.4)
Smoking status
Never 23,535 (33) 3,945 (32)
Former 27,332 (38) 4,796 (38)
Current 20,497 (29) 3,761 (30)
Alcohol consumption, g/d
, 8 22,271 (31) 3,952 (31)
8-15 14,297 (20) 2,712 (21)
16-39 20,898 (29) 3,572 (28)
$ 40 14,574 (20) 2,476 (19)
Physical activity
Inactive 14,538 (20) 2,465 (20)
Moderately inactive 19,599 (27) 3,239 (26)
Moderately active 27,220 (38) 4,393 (35)
Active 10,117 (14) 2,419 (19)
Marital status
Single 4,090 (11) 66 (1.2)
Married 29,799 (80) 4,816 (91)
Divorced 2,788 (7.4) 380 (7.1)
Widower 779 (2.1) 58 (1.1)
Educational attainment
Primary or less 22,541 (32) 4,052 (34)
Secondary 17,814 (26) 3,773 (32)
Technical 5,701 (8.2) 1,004 (8.4)
Degree 23,116 (33) 3,129 (26)
NOTE: Data given asmedians (interquartile range) or No. (%). Numbersmay not
sum to total as a result of missing values.
Abbreviations: BMI, body mass index; EPIC, European Prospective In-
vestigation into Cancer and Nutrition.
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adjusted geometric mean, 14.2 ng/mL (95% CI, 12.9 to 15.6) versus
12.8 ng/mL (95% CI, 12.4 to 13.1; P = .03). No signiﬁcant dif-
ferences by vasectomy status were observed for PSA level (total, free,
intact, free-to-total) or hK2 (all P . .05; Table 3).
DISCUSSION
In this large, prospective European study, vasectomy was not as-
sociated with risk of prostate cancer overall, with risk for high-
grade or advanced-stage tumors, or with death due to prostate
cancer. However, there was some evidence that vasectomy may be
associated with an elevated risk of low-intermediate–grade disease,
and that having had a vasectomy is associated with also having had
a PSA test.
Three of the seven previous cohort studies on vasectomy have
reported an increased risk of prostate cancer in men with
vasectomies.4,10,32 However, aside from the recent HPFS4 and the
CPS-II cohort,3 all cohort studies have had a low number of in-
cident cases with vasectomy (, 150), and so risk estimates have
been subject to substantial uncertainty. The results from the HPFS
cohort suggested a modest 10% elevated risk of overall prostate
Table 2. HR and 95% CIs for Vasectomy and Prostate Cancer in Men Enrolled in EPIC
Variable Patients, No. Minimally Adjusted HR (95% CI)* Multivariable Adjusted HR (95% CI)† P
Total prostate cancer
Without vasectomy 3,736 1.00 (reference) 1.00 (reference)
With vasectomy 641 1.05 (0.96 to 1.15) 1.05 (0.96 to 1.15)
Age at vasectomy
Without vasectomy 2,532 1.00 (reference) 1.00 (reference)
With vasectomy
, 38 years 246 1.17 (1.02 to 1.34) 1.18 (1.03 to 1.35)
$ 38 years 395 0.99 (0.89 to 1.10) 0.99 (0.89 to 1.09) 0.04‡
Years since vasectomy
Without vasectomy 3,736 1.00 (reference) 1.00 (reference)
With vasectomy
, 25 years 258 1.07 (0.94 to 1.22) 1.07 (0.94 to 1.22)
$ 25 years 378 1.06 (0.95 to 1.18) 1.06 (0.95 to 1.19) 0.9‡
Localized prostate cancer
Without vasectomy 1,826 1.00 (reference) 1.00 (reference)
With vasectomy 274 1.07 (0.94 to 1.22) 1.07 (0.94 to 1.22)
Advanced prostate cancer
Without vasectomy 545 1.00 (reference) 1.00 (reference)
With vasectomy 88 1.03 (0.82 to 1.31) 1.03 (0.82 to 1.30) 0.6§
Low-intermediate–grade prostate
cancer
Without vasectomy 2,090 1.00 (reference) 1.00 (reference)
With vasectomy 348 1.15 (1.02 to 1.29) 1.14 (1.01 to 1.29)
High-grade prostate cancer
Without vasectomy 475 1.00 (reference) 1.00 (reference)
With vasectomy 69 0.82 (0.63 to 1.07) 0.83 (0.64 to 1.07) 0.02§
Fatal prostate cancer
Without vasectomy 555 1.00 (reference) 1.00 (reference)
With vasectomy 77 0.87 (0.68 to 1.11) 0.88 (0.68 to 1.12)
Abbreviations: EPIC, European Prospective Investigation into Cancer and Nutrition; HR, hazard ratio.
*From a Cox proportional hazards model stratiﬁed by recruitment center and age at recruitment.
†From a Cox proportional hazards model stratiﬁed by recruitment center and age at recruitment, and adjusted for body mass index, smoking status, marital status,
educational attainment, alcohol consumption, physical activity, and protein from dairy sources.
‡Test for heterogeneity was by likelihood ratio test.
§Test for heterogeneity was by competing risks method.
Table 3. Adjusted Geometric Means and 95% CIs of Plasma Concentrations of Seminal Analytes by Vasectomy Status in a Subset of MenWithout Prostate Cancer in
the EPIC Study
Seminal Analytes Without Vasectomy (n = 1,327) With Vasectomy (n = 142) P*
Microseminoprotein-b, ng/mL† 12.8 (12.4 to 13.1) 14.2 (12.9 to 15.6) .03
Total PSA, ng/mL 0.87 (0.83 to 0.91) 0.86 (0.75 to 0.98) .9
Intact PSA, ng/mL 0.13 (0.12 to 0.14) 0.12 (0.10 to 0.14) .3
Free PSA, ng/mL 0.28 (0.27 to 0.29) 0.27 (0.24 to 0.30) .7
Free-to-total PSA, %† 31.7 (31.1 to 32.4) 31.3 (29.3 to 33.4) .7
Human kallikrein protein 2, ng/mL 0.029 (0.027 to 0.029) 0.029 (0.025 to 0.33) .9
Abbreviation: PSA, prostate-speciﬁc antigen.
*P values were calculated from analyses of variance adjusted for age, body mass index, recruitment center, and laboratory batch.
†For free-to-total PSA data, there were 1,325 men without vasectomy.
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cancer and an elevated risk for aggressive tumor subtypes, with
a 22% increased risk of high-grade and a 20% increased risk of
advanced-stage tumors for men with vasectomies, compared with
men without vasectomies. In contrast, both the current study and
CPS-II3 found no signiﬁcant association of vasectomy with
prostate cancer overall, high-grade or advanced-stage disease, or
death from prostate cancer. Thus, our ﬁndings do not support the
previously hypothesized role of vasectomy as a risk factor for
prostate cancer overall or for more aggressive tumors.
There is no established biologic rationale for an association of
vasectomy with prostate cancer.33 During a vasectomy, the vas
deferens is cut, blocked, or sealed to prevent the sperm from
reaching the seminal ﬂuid. Although previous studies have in-
vestigated a series of theoretical mechanisms that include immu-
nologic response,5 changes to cell proliferation,6 and endocrine
function,4,7 the biologic signiﬁcance of these pathways in humans is
unclear. This study addressed a recent suggestion that there may be
differential regulation of seminal analytes inmen after vasectomy4,34;
among 1,469 men without prostate cancer, we found little evidence
that vasectomy is associated with different blood plasma concen-
trations of PSA variants or hK2. However, signiﬁcantly higher blood
plasma concentrations of MSP were found in men with vasectomy
compared with those without. MSP is a protein abundant in the
seminal ﬂuid,35 which has been found at signiﬁcantly higher con-
centrations in the seminal plasma in infertile men when compared
with fertile men.36 However, circulating concentrations have been
previously inversely associated with prostate cancer28 and so our
observation of higher circulating concentrations ofMSP inmenwho
had undergone vasectomy does not provide evidence in favor of
vasectomy as a risk factor of prostate cancer.
A signiﬁcantly increased risk of low-intermediate grade
prostate cancer in men who had had a vasectomy in the current
study might be at least partly explained by differences in the use of
PSA testing. Men who receive a vasectomy may be more likely to
attend health-care services and have their PSA level tested, and thus
also be more likely to be diagnosed with prostate cancer, especially
low-grade disease. Evidence for this hypothesis comes both from
our ﬁnding that, in the EPIC-Oxford subcohort, men with a va-
sectomy were more likely to have had a PSA test than men without
a vasectomy, and from the HPFS cohort, which also found that
men with a vasectomy were more likely to have a history of PSA
testing than men without a vasectomy.4 There was also some
evidence for heterogeneity by age at vasectomy and alcohol intake,
but the implications of these subgroup analyses are unclear.
Evidence from the European Randomized Study of Screening
for Prostate Cancer suggests that when PSA testing is offered to all
men, it reduces prostate cancer mortality by approximately 28% at
13 years of follow-up.37 If we assume that the use of PSA testing is
20% among men who have not had a vasectomy and 40% among
men who have (data from EPIC-Oxford), it is possible that in-
creased screening in the latter could result in a 5.6% reduced risk of
death due to prostate cancer. This suggests that although it is
possible that an adverse effect of vasectomy on the risk of po-
tentially lethal prostate cancer is being partly masked by a beneﬁcial
effect of increased PSA testing, any such bias is likely small.
Nevertheless, it remains a limitation of the current investigation
that, because of limited information on PSA testing, we were
unable to more fully address the role of PSA testing in the proposed
association of vasectomy with prostate cancer. This should be
considered in future studies.
Due to the lack of updated data collection for vasectomy
status, it is possible that our results were biased by misclassiﬁcation
of men who had undergone vasectomy as being nonvasectomized.
However, for the EPIC-Oxford subcohort, updated data on va-
sectomy status were available and showed that 5.1% of men
without a vasectomy at baseline reported having had a vasectomy
during the 10 years after recruitment. Furthermore, a recent report
suggested that a small misclassiﬁcation of men who had undergone
vasectomy as nonvasectomized would likely result in only a min-
imal underestimate of any association3 of vasectomy with prostate
cancer risk.
In conclusion, this investigation of 84,753 men in the EPIC
cohort did not ﬁnd a signiﬁcant association between vasectomy
and overall prostate cancer, high-grade or advanced-stage tumors,
or death due to prostate cancer. The small increase in the risk of
low-intermediate–grade prostate cancer in men who had had
a vasectomy may be due to differences in health-monitoring
behaviors.
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